Washington state ranks No. 2 nationwide for annual video game industry economic output at $11.6B

(Halo Infinite Photo)

Washington state’s video games industry overtook Texas last year and claimed the No. 2 spot for total economic output, as the U.S. video game industry grew to new heights yet again.

Those are two takeaways from a new report published by the Entertainment Software Association (ESA), the games industry’s trade organization in the U.S.

In Washington state, the local games industry represents 48,808 jobs, with an economic output of $11.6 billion. This puts it ahead of all other states besides California, which has an effectively insurmountable lead. A little over half of all game development nationwide is done in California, which accounts for $51 billion of the more than $90 billion in economic output generated nationwide in 2019.

The ESA defines “economic output” as “the total value of the goods and services produced in the economy.”

Washington has been an important overall part of the U.S.

Read More

Wipro’s Annual State of Cybersecurity Report Finds Increasing Adoption of AI in Cybersecurity to Tackle Advanced Adversaries

Nearly half (49%) of organizations plan to extend Cognitive and AI capabilities for security to detect and respond to attacks faster

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today released its annual State of Cybersecurity Report (SOCR) that presents changing perspectives of cybersecurity globally.

The report provides fresh insights on how Artificial Intelligence (AI) will be leveraged as part of defender stratagems as more organizations lock horns with sophisticated cyberattacks and become more resilient. There has been an increase in R&D with 49% of the worldwide cybersecurity related patents filed in the last four years being focussed on AI and Machine Learning (ML) application. Nearly half the organisations are expanding cognitive detection capabilities to tackle unknown attacks in their Security Operations Center (SOC).

The report also illustrates a paradigm shift towards cyber resilience amid the rise in global

Read More

YouTube cancels its annual Rewind video in 2020

“But 2020 has been different,” the company said in a statement posted on its Twitter page. “And it doesn’t feel right to carry on as if it weren’t. So, we’re taking a break from Rewind this year.”

In some ways, Google-owned YouTube has had a good year — with so many people staying home to reduce the spread of the coronavirus, views have skyrocketed. During company earnings last month, YouTube reported paid subscribers had increased to 30 million, up from 20 million at the end of last year.

But YouTube has also been in the crosshairs of a fraught election season, where social media companies have been criticized for their role in allowing misinformation to spread.

YouTube’s Rewind video hasn’t always been a fun-loving, scandal-free, 10-minute year-in-review. Its 2018 look-back was hit with significant backlash and quickly became the most disliked video in YouTube’s history. It still has more

Read More

Tonix Pharmaceuticals Outlines New Statistical Method to Analyze Future PTSD Studies at the 3rd Annual Neuropsychiatric Drug Development Summit

The MarketWatch News Department was not involved in the creation of this content.

CHATHAM, N.J., Nov 12, 2020 (GLOBE NEWSWIRE via COMTEX) —
Increasing Placebo Responses in PTSD Drug Trials Raise Questions About Current Methods of Measuring or Analyzing PTSD Symptom Change Over Time

The U.S. 21 Century Cures Act Provides Direction on New Statistical Analyses Using Simulations

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, outlined a new statistical method to analyze future Posttraumatic Stress Disorder (PTSD) drug studies and presented a retrospective analysis using the new method of the Phase 3 HONOR study (P301) of TNX-102 SL (cyclobenzaprine HCl sublingual tablets), for the treatment of military-related PTSD at the 3 Annual Neuropsychiatric Drug Development Summit today.

“The paradox that confounds modern PTSD studies is that the placebo response

Read More